Drugs / Trifluridine/tipiracil
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06238843 Comparator | Jun 2024 → Dec 2026 expected | gastroesophageal adenocarcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06238843 ↗ |
| Route | Oral | “FTD/TPI 35 mg/m2 up to a maximum of 80 mg orally twice a day” NCT06238843 ↗ |